Should I Buy IBO? IBO 2026 Analysis

Should You Buy Impact Biomedical Inc (IBO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.480

1 Day change

3.25%

52 Week Range

6.170

Analysis Updated At

2026/01/29

Not a good buy right now for a Beginner long-term investor with $50k–$100k. IBO is in a clear downtrend (bearish moving averages and negative MACD), has extremely weak and tiny revenue ($18k in 2025/Q3) with sharply worsening losses, and there are no near-term news catalysts or strong proprietary trading signals to justify an impatient entry.

Technical Analysis

Trend is bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating sustained downside pressure. MACD histogram (-0.00295) is below zero (bearish) though contracting (selling pressure may be easing, but not reversed). RSI_6 at ~39 is neutral-to-weak (not oversold enough to imply a strong bounce). Key levels: support S1=0.447 then S2=0.431; resistance Pivot=0.473 then R1=0.499 and R2=0.515. With price ~0.4609, the stock sits below the pivot and would need to reclaim ~0.473–0.499 to suggest improving momentum. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently. Pattern-based short-term odds provided: ~70% chance of -0.36% next day, +1.06% next week, +9.11% next month—this suggests a possible small rebound over a month, but it’s not backed by strong technical reversal signals today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options sentiment is hard to read because most fields are blank (open interest and volume data not populated), which often implies very low options activity/liquidity. The put/call ratios shown as 0.0 typically indicate no meaningful put activity recorded (or missing data). Historical volatility is extremely high (~214.69), which aligns with a highly speculative, high-risk price behavior rather than stable long-term investing characteristics.

Technical Summary

Sell

Buy

Positive Catalysts

No positive news catalysts in the last week. Technically, selling pressure may be easing slightly (MACD contraction), and the pattern-based model suggests the possibility of a modest 1-month upside (+9.11%), but this is not confirmed by strong reversal signals. No significant hedge fund/insider trend signals were noted (both neutral).

Neutral/Negative Catalysts

suggests unstable price action. No supportive proprietary buy signals (AI Stock Picker / SwingMax). No recent congress trading data or notable influential-figure activity available to indicate confidence.

Financial Performance

Latest reported quarter: 2025/Q3. Revenue was $18,000 (0.00% YoY), indicating no meaningful growth. Net income fell to -$1.47M (-134.61% YoY), and EPS dropped to -0.12 (-300% YoY), showing losses are accelerating. Overall, fundamentals look deteriorating rather than improving.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target change data was provided, which is common for micro-cap/penny-type names. With no visible Wall Street coverage in the dataset, there is no credible pro-cons consensus to lean on; decision should rely on the bearish technicals and weak quarterly fundamentals.

Analyst Rating

Wall Street analysts forecast IBO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBO is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy